New technology and health care costs--the case of robot-assisted surgery.

@article{Barbash2010NewTA,
  title={New technology and health care costs--the case of robot-assisted surgery.},
  author={Gabriel I. Barbash and Sherry Glied},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 8},
  pages={
          701-4
        }
}
Technological innovation in health care is an important driver of cost growth. Doctors and patients often embrace new modes of treatment before their merits and weaknesses are fully understood. These technologies can lead to increases in costs, either because they are simply more expensive than previous treatments or because their introduction leads to an expansion in the types and numbers of patients treated. We examined these patterns as they apply to the case of robot-assisted surgery… 
View on PubMed
doctorsandmanagers.net
799 Citations
Highly Influential Citations
30
Background Citations
250
Methods Citations
31
Results Citations
11

799 Citations

Citation Type

Citation Type

Robotic surgery in urological oncology: patient care or market share?
TLDR
The surgical robot should be used when cost-effective, but traditional open and laparoscopic techniques also need to be continually fostered.
Laparoscopy, Robotics, and Endoscopy
TLDR
Advances such as ESD, EMR, and CLER allow the possibility of treating neoplasia through minimally invasive and endoscopic approaches, minimizing the physical and emotional impact of surgery.
Comparative effectiveness research on robotic surgery.
TLDR
The use of robotic-assisted surgery has substantially increased, beginning with urologic procedures and expanding to include gynecologic procedures and many others, and may be linked to a number of converging factors, including better ergonomics for the surgeon, marketing campaigns, and the national fascination with technology and innovation.
Use of robotics in oncology surgery.
Robotic surgery is an exciting technology that allows the surgeon to sit at a computer console near the operating table, using mechanical arms with surgical instruments attached to them. This type of…
Robotic versus laparoscopic surgery for rectal cancer and cost-effectiveness analysis
TLDR
The authors conclude that robotic TME for rectal cancer is feasible with similar short-term oncologic and QOL outcomes compared with laparoscopic TME, and note that whether the greater manoeuvrability and visibility afforded by the robotic approach can result in better outcomes than those of Laparoscopic surgery can be answered by future, more systematic studies considering also the costs of robotic-assisted surgery.
Robot-assisted plastic surgery.
The end of robot-assisted laparoscopy? A critical appraisal of scientific evidence on the use of robot-assisted laparoscopic surgery
TLDR
The use of robotics should be limited to well-powered, randomized clinical trials in a limited field of research, in an era of worldwide economic crisis.
Are Costs of Robot-Assisted Surgery Warranted for Gynecological Procedures?
TLDR
The present review of the literature shows that robot-assisted surgery is consistently more expensive than video-laparoscopy and in many cases open surgery, and the costs of robotic surgery will have to be reduced.
Cost Considerations for Robotic Surgery.
Robotic surgery - advance or gimmick?
...
...

References

SHOWING 1-3 OF 3 REFERENCES
Comparative effectiveness of minimally invasive vs open radical prostatectomy.
TLDR
Men undergoing MIRP vs RRP experienced shorter length of stay, fewer respiratory and miscellaneous surgical complications and strictures, and similar postoperative use of additional cancer therapies but experienced more genitourinary complications, incontinence, and erectile dysfunction.
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
TLDR
The comparative short- and long-term benefits and harms of therapies for clinically localized prostate cancer and how patient and tumor characteristics affect the outcomes of these therapies, overall and differentially are determined.
491 TIME TRENDS IN THE UTILIZATION OF HIGHER-COST TREATMENTS FOR PROSTATE CANCER, 2002-2007